Detalles de la búsqueda
1.
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
Kidney Int
; 105(6): 1306-1315, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38552841
2.
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort.
Rheumatology (Oxford)
; 63(2): 472-481, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37228011
3.
Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis.
Clin Immunol
; 254: 109695, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479123
4.
Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
Am J Respir Crit Care Med
; 205(6): 674-684, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34851799
5.
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
Crit Care Med
; 50(3): 398-409, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34612846
6.
New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.
Ann Rheum Dis
; 80(5): 641-650, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33257497
7.
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).
Ann Rheum Dis
; 77(2): 212-220, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29066464
8.
Atacicept-it's not over until the wolf-lady sings (or maybe howls).
Rheumatology (Oxford)
; 62(4): 1359-1361, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36087007
9.
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study.
BMC Musculoskelet Disord
; 18(1): 174, 2017 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-28449657
10.
Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.
Ann Rheum Dis
; 78(11): e124, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30352886
11.
Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial.
Open Forum Infect Dis
; 9(1): ofab608, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35024375
12.
Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
Arthritis Rheumatol
; 73(7): 1301-1310, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33538094
13.
Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population.
Rheumatol Ther
; 7(1): 89-99, 2020 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-31734871
14.
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Respir Med
; 8(10): 963-974, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866440
15.
Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting.
J Rheumatol
; 45(2): 170-176, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29142041
Resultados
1 -
15
de 15
1
Próxima >
>>